Friday, June 26, 2026

Premature Rupture of Membranes

2-3%

of all pregnancies affected

33%

of preterm births

10-32%

recurrence risk

24-37w

typical presentation

🔍 DIAGNOSIS

Sterile speculum exam (GOLD STANDARD)
Look for pooled fluid in posterior fornix
Nitrazine test (alkaline = blue-green)
Ferning test (salt crystals)
Ultrasound (AFI assessment)
PAMG-1 if equivocal

⚠ SCREEN FOR COMPLICATIONS

Chorioamnionitis (fever + signs)
Placental abruption (bleeding + pain)
Cord prolapse (cord visible)
Fetal distress (abnormal CTG)

Any complication → STAT DELIVERY

📍 MANAGEMENT BY GA

Less than 22-24w: Previable (shared decision)
22-34w: EXPECTANT management
34-37w: Depends on GBS status
37w and above: Deliver (term reached)

💊 MEDICATIONS - ALL GA LESS THAN 34-35w

Corticosteroids

Betamethasone 12mg IM x2 at 24h apart

Antibiotics (latency)

Ampicillin + Macrolide x7-10 days

GBS prophylaxis (labor)

Penicillin G or Ampicillin IV

✓ MATERNAL SURVEILLANCE

Daily temp monitoring
Daily symptom check
Weekly speculum exams (NO digital)
Return if fever/pain/discharge/decreased FM
Bed rest NOT recommended

✓ FETAL SURVEILLANCE

Continuous CTG if greater than 24w viable
Daily fetal movement counting
Twice-weekly NST/CTG minimum
Ultrasound q2-4 weeks
Assess growth, AFI, placenta

⏱ IMMEDIATE STEPS

Confirm diagnosis (sterile speculum)
Vital signs + obstetric exam
Fetal assessment (CTG if viable)
Screen for complications
CBC + cultures + GBS swab
Ultrasound: confirm, assess GA, AFI
START corticosteroids STAT

🏥 ADMISSION CRITERIA

Any PPROM less than 34 weeks (typically)
First 48-72 hours minimum
Complications (fever, bleeding, distress)
Unreliable or no home support
GA less than 28 weeks (almost always)

🚨 RED FLAGS - DELIVER IMMEDIATELY

Chorioamnionitis:
Fever + tachycardia + tenderness + discharge

Abruption:
Bleeding + pain + shock signs

Cord Prolapse:
Cord visible through cervix

Fetal Distress:
Late decelerations + bradycardia

📋 DOCUMENTATION ESSENTIALS

Must include: Diagnosis method + results • Gestational age (LMP or US) • Red flag assessment • Complications screening • Medications given with times • Monitoring plan • Counseling and informed consent • Follow-up arranged

Version 1.0 | June 2026 | Swaraj Hospital and Research Institute, Bolangir

For complete details, refer to full PPROM Protocol Document

Protocol on Management of Severe Headache

Protocol on Management of Severe Headache - Swaraj Hospital & Research Institute

Swaraj Hospital & Research Institute

Protocol on Management of Severe Headache

Clinical Guidelines & Emergency Management Pathways

Version: 1.0

Effective Date: June 2026

Location: Bolangir

Department: Emergency & Neurology

📋

Executive Summary

This protocol provides standardized guidelines for the assessment, investigation, and management of severe headache presentations at Swaraj Hospital & Research Institute. While most acute headaches are primary (benign) in nature, 15-25% of severe presentations indicate serious underlying pathology requiring urgent intervention including subarachnoid hemorrhage, meningitis, acute stroke, or space-occupying lesions.

Protocol Objectives

Rapid identification of red-flag warning symptoms
Appropriate use of diagnostic investigations
Timely specialist referral
Evidence-based pain management
Clear admission and discharge criteria

Introduction & Definitions

Definition of Severe Headache

Severe headache is acute cranial pain of significant intensity (≥7/10 on visual analog scale) affecting the head or upper neck region, requiring urgent assessment to identify life-threatening causes and provide appropriate management.

Clinical Significance

Headache is the 3rd most common ED presentation
85-90% are primary headaches (migraine, tension, cluster)
10-15% have secondary causes requiring intervention
Misdiagnosis of dangerous causes leads to poor outcomes
Early recognition and management reduce morbidity and mortality

Key Principles

High index of suspicion for dangerous causes
Rapid assessment minimizes delays
Appropriate imaging based on red flags
Clear referral pathways established

⚠

Red Flag Symptoms

ANY red flag present requires immediate investigation and likely admission. Do not discharge with reassurance alone.

⚡

Thunderclap Headache

Maximal intensity within 1-2 minutes; suggestive of SAH, dissection, RCVS. STAT imaging required.

🌡

Fever + Neck Stiffness

Classic meningitis triad; requires immediate LP and antibiotics within 60 minutes.

🧠

Focal Neurological Deficit

Weakness, aphasia, ataxia; indicates stroke or mass lesion. Emergency imaging.

👁

Visual Symptoms

Diplopia, visual field loss, photophobia with vision loss; suggests raised ICP or vascular event.

💭

Altered Consciousness

Confusion, disorientation, reduced LOC; emergency imaging and monitoring required.

❌

First/Worst Headache of Life

New onset severe, worst ever experienced; always investigate until proven benign.

Additional Risk Factors

Immunocompromised patients
Age >50 (increased risk of GCA, stroke)
History of malignancy
Pregnancy or postpartum period
Anticoagulation therapy
Recent head/neck trauma
Sudden exertional onset

Initial Assessment & Clinical Evaluation

History Taking Components

Onset & Temporal Pattern

Sudden vs gradual onset
Progressive vs stable
Frequency and duration
Time of day when worst

Headache Characteristics

Pain quality: throbbing, pressure, sharp, dull
Severity: 0-10 scale
Location: unilateral, bilateral, focal, diffuse
Radiation pattern

Associated Features

Fever, chills
Nausea, vomiting
Visual symptoms
Weakness, numbness
Confusion, behavioral changes
Neck stiffness

Vital Signs Assessment

Temperature: Fever suggests infection (meningitis, encephalitis)
Blood Pressure: Hypertension may indicate emergency (ICH, eclampsia)
Heart Rate & Rhythm: Tachycardia suggests systemic illness
Respiratory Rate: Altered breathing suggests CNS involvement
Oxygen Saturation: Hypoxia requires intervention

Neurological Examination (Minimum Standards)

Exam Component	What to Assess	Red Flag Finding
Level of Consciousness	Alert vs lethargic vs confused	Altered LOC or confusion
Pupils	Size, symmetry, reactivity to light	Unequal or fixed pupils
Visual Fields	Confrontation testing	Visual field defect
Motor Strength	Arm drift, leg strength (0-5 scale)	Asymmetric weakness
Cerebellar Signs	Gait, balance, coordination	Ataxia or dysmetria
Meningeal Signs	Neck stiffness, Kernig, Brudzinski	Any meningeal sign positive
Fundoscopy	Look for papilloedema	Papilloedema present

Diagnostic Investigations

Imaging Selection

CT Brain (Non-contrast)

First-line Imaging

Indications: All thunderclap headaches, first/worst headache, focal deficits, altered LOC, fever + meningeal signs
Timing: Within 30 minutes
Sensitivity: 95%+ for SAH in first 6 hours
Advantages: Fast, readily available, rules out hemorrhage and mass

CT Angiography (CTA)

Enhanced Vascular Imaging

Indications: SAH suspected, thunderclap with normal CT, arterial dissection suspected
Sensitivity: Excellent for aneurysm and arterial dissection
Timing: STAT if SAH suspected

MRI with MR Venogram

Advanced Imaging

Indications: Subacute/chronic progressive headache, suspected thrombosis, posterior fossa pathology
Advantages: Better tissue resolution, no radiation
Disadvantage: Slower, less accessible acutely

Lumbar Puncture (CSF Analysis)

Meningitis/Encephalitis Diagnosis

Indications: Meningitis strongly suspected, CSF pressure assessment
Timing: Within 60 minutes if bacterial meningitis
IMPORTANT: Perform CT first to rule out contraindications (mass, herniation)
Tests: Cell count, glucose, protein, culture, PCR, Gram stain

Blood Investigations

Test	Indication	What It Detects
CBC	Suspected infection	Elevated WBC suggests infection
ESR/CRP	Age >50 with headache	Inflammation (GCA, vasculitis)
Blood Cultures	Before antibiotics if sepsis	Bacteremia (meningitis)
PT/INR	If anticoagulated	Bleeding risk assessment
Virology PCR	Meningitis suspected	Viral pathogens

Investigation Decision Tree

Assess for Red Flags

Thunderclap, fever + neck stiffness, focal deficit, visual symptoms, altered LOC, first/worst headache?

If RED FLAGS present → STAT CT Brain

Complete within 30 minutes. Notify Neurology and prepare for possible ICU admission.

CT Normal? → Consider next step

If meningitis suspected → LP. If thunderclap → CTA. If improving → Consider discharge.

CT Abnormal → Treat per finding

SAH, ICH, mass, or other pathology identified. Consult appropriate specialist (Neurology, Neurosurgery).

Emergency Management Algorithm

Stabilization (First 10 minutes)

Establish IV access (two lines if severe), Oxygen (SpO₂ ≥94%), Cardiac monitor, NPO status, Quiet dark environment

Rapid Assessment for Red Flags

If red flags present: STAT CT/CTA, Notify Neurology, Request ICU bed. If negative: Proceed to Step 3.

Acute Pain Management

Paracetamol 1g IV/PO OR Ketorolac 30mg IV/IM. Avoid opioids (mask deterioration) and NSAIDs if hemorrhage suspected.

Supportive Care

Anti-emetics if nausea, IV fluids if dehydrated, dark/quiet room for migraine, temperature management if febrile.

Decision & Disposition

If imaging normal and red flags absent + pain controlled → Safe for discharge with return precautions.

Management of Specific Conditions

Suspected Subarachnoid Hemorrhage (SAH)

Immediate Actions:

STAT CT, Neurology + Neurosurgery consult
ICU admission, continuous neuro monitoring
Nimodipine 60mg IV 4-hourly (vasospasm prevention)
Target SBP <160, maintain oxygenation
Avoid hypertension and hypoxia

Suspected Meningitis

STAT Antibiotic Therapy (Do not delay for LP)

Ceftriaxone 2g IV 12-hourly
Vancomycin 15-20mg/kg IV 8-12 hourly
Ampicillin if >50 years or immunocompromised
Dexamethasone 10mg IV with first antibiotic
LP after CT to rule out contraindications
ICU admission

Suspected Acute Stroke

Stroke Protocol:

STAT CT/CTA, Neurology consult
Activate stroke alert
Consider thrombolysis if within therapeutic window
ICU monitoring

Treatment Protocols

Primary Analgesics

Paracetamol (Acetaminophen)

1g IV or PO every 4-6 hours | Maximum 4g in 24 hours

Note: First-line, safe in pregnancy, avoid in severe hepatic disease

Ketorolac (NSAID)

30mg IV/IM single dose, then 10mg PO TID

Contraindications: Renal disease, GI bleed, pregnancy, hemorrhage suspected

Indomethacin

25-50mg PO/rectal TID for 7 days

Best for: Tension headache, cluster headache prophylaxis

Anti-emetics

Prochlorperazine

10mg IV/IM/PO every 6-8 hours

Ondansetron

4-8mg IV/PO every 8 hours

Migraine-Specific Therapy

Sumatriptan (Triptan)

6mg subcutaneous OR 50mg oral (only if migraine confirmed)

Propranolol (Prophylaxis)

40-80mg oral daily-BID (for recurrent migraine >2/month)

Amitriptyline (Prophylaxis)

10-75mg oral at bedtime (for chronic migraine)

Supportive Care Measures

✓ Dark, quiet room (minimizes migraine triggers)
✓ Head elevation 30 degrees
✓ Oxygen if SpO₂ <94%
✓ IV fluids if dehydrated
✓ Temperature control if febrile
✓ Position changes for comfort

Medications to AVOID

Do Not Use If:

Opioids: Mask neurological deterioration, risk of dependence
NSAIDs: Suspected hemorrhage (SAH, ICH, anticoagulated patient)
Excess Analgesics: Risk of medication overuse headache (>10 days/month)

Admission, Discharge & Referral

ADMISSION CRITERIA

Any red flag symptom present
First/worst headache of life
Progressive or unrelenting pain
Fever + meningeal signs
Focal neurological deficit
Altered consciousness
Abnormal imaging findings
Failed outpatient management

SAFE DISCHARGE (ALL required)

Complete neuro exam normal
No red flag symptoms
Imaging normal (if done)
Pain controlled/improving
Reliable patient with support
Clear follow-up arranged
Return precautions explained

NEUROLOGY REFERRAL

Suspected SAH/ICH/stroke
Space-occupying lesion
Recurrent/chronic headache
Migraine requiring prophylaxis
Atypical features
Undiagnosed after workup

Return Precautions for Discharged Patients

Advise Patient to Return Immediately If:

Headache progressively worsens
New weakness, numbness, or difficulty speaking
Vision changes or eye pain
Neck stiffness or fever develops
Confusion or altered consciousness
Seizures occur
Headache different in character from usual

Documentation Requirements

Element	What to Document
Vital Signs	Temperature, BP, HR, RR, SpO₂ with time recorded
Pain Severity	0-10 scale, location, character, onset
Red Flag Assessment	Specific findings or explicitly "no red flags identified"
Neurological Exam	LOC, pupils, motor, cerebellar signs, meningeal signs
Imaging	Type, findings, time completed
Medications	Drug, dose, route, time, response
Final Diagnosis	Primary vs secondary, specific type
Disposition	Admitted to (ward/ICU), discharged, or referred

📚

References & Guidelines

Hainer BL, Matheson EM. Approach to acute headache in adults. Am Fam Physician. 2013;87(10):682-687.
Indian Council of Medical Research (ICMR). Standard Treatment Workflow for Management of Headache. Department of Health Research, Ministry of Health and Family Welfare, Government of India. 2024.
South Eastern Sydney Local Health District. Assessment and Management of Headaches in Adults within SESLHD Emergency Departments. SESLHDGL/060. January 2025.
Edvardsson B, Edvinsson L. Principles in evaluation of headache. Neurol Clin. 2019;37(4):745-760.
Orr SL, et al. 2025 Guideline Update to Acute Treatment of Migraine for Adults in the Emergency Department. American Headache Society. 2025.
International Headache Society. International Classification of Headache Disorders (ICHD-3). 3rd ed. 2024.

Disclaimer

This protocol is a clinical guideline based on best practices and available evidence. Individual clinical judgment and patient-specific factors must guide treatment decisions. Any deviations from this protocol should be documented with clinical reasoning.

↑ Back to Top

Tuesday, June 23, 2026

Summer Heatwave Skin Protection

Summer Heatwave Skin Protection Infographic

Premanstrual Tension

Monday, June 22, 2026

Yoga is Not a Simple Exercise: How Yoga Differs from "Exercise" — A Clinician's Lens

Sunday, June 21, 2026

Understanding Intrahepatic Cholestasis of Pregnancy (ICP)

Understanding Intrahepatic Cholestasis of Pregnancy (ICP) - A Comprehensive Guide

✍️ Medical Education

Understanding Intrahepatic Cholestasis of Pregnancy (ICP)

A comprehensive guide to clinical features, diagnosis, and evidence-based management

By Dr. Sujnanendra Mishra, MD (Ob & Gyn)

Swaraj Hospital & Research Institute, Bolangir, Odisha

What is Intrahepatic Cholestasis of Pregnancy?

Intrahepatic Cholestasis of Pregnancy (ICP) is the most common liver disease specific to pregnancy. It is characterized by impaired bile acid excretion from the liver, leading to bile acid accumulation and elevated bile acid levels in maternal blood.

ICP is an inflammatory disease of multifactorial etiology that typically presents with new-onset pruritus (intense itching) in the late second or third trimester, often involving the palms and soles, accompanied by elevated serum bile acids.

Key Clinical Feature

The hallmark of ICP is pruritus without a visible rash. This distinguishes it from other dermatological conditions and is a critical clinical clue that should prompt immediate bile acid testing.

0.3-0.5%

Prevalence in Western populations

45-70%

Recurrence in subsequent pregnancies

Epidemiology & Global Prevalence

The prevalence of ICP varies significantly across different populations and geographic regions:

Western Europe: 0.3-0.7% of pregnancies
Hispanic populations: Up to 5.6% (significantly higher)
Asian populations: Higher prevalence, especially from India and Pakistan
Indigenous populations: Some regions report rates up to 22% (e.g., Araucanian Indians in Chile)
Caucasian populations: 0.32% (lower baseline risk)

                    Risk Factors for ICP Development
                    Prior history of ICP (strongest risk factor)
Multiple gestation (twin or higher-order pregnancy)
Hepatobiliary disease history (especially Hepatitis C)
Genetic predisposition and mutations (ABCB4, ABCB11, ATP8B1)
Assisted reproductive technology (ART) stimulation with high estrogen (RR 3.8)
Advanced maternal age
Progesterone supplementation in some cases

                

Clinical Symptoms & Presentation

Patients with ICP typically present with characteristic symptoms that develop acutely:

Primary Symptoms

Intense Pruritus: Sudden-onset severe itching, often worse at night and disturbing sleep
Palmar/Plantar Involvement: Characteristic itching of palms and soles; may affect other areas
Absence of Rash: Pruritus occurs without visible skin manifestation (key distinguishing feature)
Psychological Impact: Significant distress from itching intensity and sleep disruption
Excoriations: Severe scratching may result in skin damage

⚠️ Important Clinical Note

The severity of pruritus does NOT correlate with maternal bile acid levels or fetal risk. Some patients with minimal symptoms have dangerous bile acid levels, while others with severe pruritus have lower levels. This makes routine monitoring essential regardless of symptom severity.

Timing of Presentation

ICP typically manifests in the late second trimester to early third trimester, aligning with peak estrogen and progesterone levels. Early diagnosis (before 18 weeks) is rare and suggests possible underlying hepatic disease requiring hepatology consultation.

How ICP Develops: The Molecular Mechanism

The pathophysiology of ICP is multifactorial, involving genetic, hormonal, and inflammatory mechanisms:

Step 1: Hormonal Trigger

Elevated estrogen and progesterone in late pregnancy inhibit bile acid flow and hepatic excretion pathways

Step 2: Transporter Dysfunction

Impaired hepatocellular transporters (ABC transporters like ABCB4, ABCB11) reduce bile acid elimination

Step 3: Bile Acid Accumulation

Bile acids accumulate intracellularly and are released into maternal blood; stasis triggers inflammation

Step 4: Inflammatory Response

Proinflammatory cytokines are released; accumulation in tissues triggers symptoms and fetal effects

Key Molecular Mechanisms

Taurine-Conjugate Accumulation: Toxic bile acid forms accumulate in fetal cardiac muscle, increasing arrhythmia risk
Oxytocin Receptor Activation: Bile acids increase oxytocin receptors in uterine muscle, elevating preterm labor risk
Placental Dysfunction: Bile acid accumulation in placental tissue may cause vasospasm and reduced fetal perfusion
Genetic Mutations: Alterations in genes encoding bile acid transporters increase ICP susceptibility

Diagnosis & Laboratory Investigation

Diagnosis of ICP requires clinical suspicion followed by laboratory confirmation:

Diagnostic Criteria

                    Clinical + Laboratory Confirmation
                    Clinical: New-onset pruritus without rash in pregnancy
Laboratory: Serum total bile acids (TBA) > 10 µmol/L (fasting) OR > 14 µmol/L (postprandial)

                

Risk Stratification by Bile Acid Levels

< 40

Low Risk (expectant management)

40-100

Moderate Risk (early delivery consideration)

> 100

High Risk (significant fetal danger)

Laboratory Tests

Serum Total Bile Acids (TBA): Primary diagnostic test; no fasting required
Liver Function Tests (LFTs): ALT, AST may be mildly to moderately elevated; ALT often more specific
Bilirubin Levels: Usually normal or mildly elevated; jaundice is uncommon
Differential Diagnosis: Rule out viral hepatitis, gallstones, preeclampsia, HELLP syndrome

Critical Clinical Pearl

Pruritus may precede elevated bile acids by 1-2 weeks. If initial TBA is normal but pruritus persists, repeat testing in 7-14 days. Do not falsely reassure patients based on a single normal bile acid level with ongoing symptoms.

Management & Treatment Strategy

ICP management requires a multidisciplinary approach combining pharmacological therapy, antenatal surveillance, and individualized delivery planning.

First-Line Pharmacological Treatment: Ursodeoxycholic Acid (UDCA)

                    UDCA Dosing & Administration
                    Initial Dose: 10-15 mg/kg/day (typically 300 mg daily)
Maximum Dose: 20 mg/kg/day (typically 300-900 mg divided into 2-3 doses)
Onset of Action: 1-2 weeks for symptom relief
Mechanism: Reduces bile acid reabsorption in the bowel and intrahepatic accumulation
Safety: Well-tolerated; adverse effects minimal (nausea, mild dizziness)

                

Important Treatment Limitation

UDCA improves maternal pruritus but does NOT prevent fetal complications. No evidence supports UDCA reducing stillbirth risk, preterm birth, or other adverse perinatal outcomes. Treatment should focus on symptom relief while obstetric management addresses fetal safety.

Obstetric Management

Antenatal Surveillance

Initiate at time of diagnosis (if gestational age permits intervention for abnormal testing)
Once or twice-weekly non-stress tests (NST)
Measurement of deepest vertical pocket of amniotic fluid
Serial growth ultrasounds at clinician discretion (FGR uncommon with ICP)

Delivery Timing

TBA < 40 µmol/L

Expectant management; plan delivery at term (≥37 weeks)

TBA 40-100 µmol/L

Consider delivery at 36-37 weeks; individualize based on clinical factors

TBA > 100 µmol/L

Strong recommendation for delivery by 36 weeks or earlier; highest fetal risk

Multidisciplinary Team Approach

Optimal ICP management requires coordinated care:

Obstetrics: General obstetric care and antenatal surveillance
Maternal-Fetal Medicine (MFM): Refer if TBA > 40 µmol/L or early diagnosis
Hepatology: Refer if TBA > 100 µmol/L or diagnosis before third trimester
Neonatology: Preparation for potential preterm delivery complications
Pharmacy & Nursing: Patient education and medication management

Maternal & Fetal Complications

While maternal prognosis is generally favorable, ICP carries significant fetal risk that demands careful management.

Maternal Complications

Severe Pruritus: Intense itching causing psychological stress, sleep disturbance, and potential skin damage from scratching
Preeclampsia (3-4x increased risk): Incidence rises from 2.4% to 7.8%; earlier ICP onset correlates with earlier preeclampsia (2-4 weeks)
Coagulopathy Risk: Potential vitamin K malabsorption and prolonged prothrombin time from bile acid stasis
Cardiac Arrhythmias: Direct arrhythmogenic effect of bile acids on cardiomyocytes (no significant clinical consequences)
Gestational Diabetes: Increased incidence from 8.5% to 13.6%; requires glucose monitoring

Fetal & Neonatal Complications

🚨 Most Serious: Sudden Stillbirth

The most concerning fetal complication is sudden intrauterine fetal death. The mechanism appears related to bile acid accumulation in fetal cardiac muscle causing arrhythmias and sudden cardiac arrest. Critically, NO PREDICTIVE MONITORING exists for stillbirth—it can occur suddenly in otherwise healthy pregnancies.

Preterm Birth: Increased incidence due to bile acid-mediated oxytocin receptor activation in uterine muscle
Meconium-Stained Amniotic Fluid: Fetal colonic stimulation from bile acid exposure
Respiratory Distress Syndrome: Risk if preterm delivery occurs
Neonatal Intensive Care Admission: Increased need for NICU monitoring and support
Birth Asphyxia: Risk from placental dysfunction or acute fetal distress

Long-Term Effects

Children born to mothers with ICP have increased risk of:

Elevated body mass index (BMI) by age 16
Dyslipidemia and metabolic abnormalities
Potentially increased cardiovascular risk profile

Risk Correlation: Bile Acid Levels Matter

Fetal risk directly correlates with bile acid concentration. The highest correlation for stillbirth occurs with TBA ≥ 100 µmol/L. This is why bile acid measurement and risk stratification are critical for management decisions.

Key Takeaways & Clinical Practice Points

Six Essential Principles

Early Recognition is Critical: New-onset pruritus without rash in 2nd-3rd trimester is ICP until proven otherwise. Prompt serum bile acid testing prevents diagnostic delays.
Risk Stratification Guides Management: Bile acid levels (not symptom severity) determine fetal risk and delivery timing. TBA > 40 = refer to MFM; TBA > 100 = high risk requiring hepatology input.
UDCA Treats Symptoms, Not Prevention: First-line therapy improves maternal pruritus within 1-2 weeks but provides no fetal protection. Symptom relief should not replace obstetric vigilance.
Fetal Surveillance is Essential: Antenatal monitoring (NSTs, amniotic fluid assessment) from diagnosis onwards. Stillbirth risk is unpredictable despite monitoring—individualized delivery timing is crucial.
High Recurrence in Future Pregnancies: 45-70% of women with ICP will experience recurrence. Early recognition and aggressive management in subsequent pregnancies is vital.
Excellent Maternal Prognosis: Pruritus and liver biochemistry resolve rapidly post-delivery (usually within days to weeks). However, women with ICP have increased long-term risk of hepatobiliary disease requiring follow-up.

Patient Education Essentials

Counsel patients about:

Expected pruritus resolution within days after delivery
High recurrence rate in subsequent pregnancies
Importance of medication compliance and regular monitoring
Attendance at all scheduled antenatal visits and testing
Need for postpartum follow-up if liver abnormalities persist beyond 4-6 weeks

When to Refer to Specialists

Maternal-Fetal Medicine (MFM): Any patient with TBA > 40 µmol/L or diagnosis in first/early second trimester
Hepatology: TBA > 100 µmol/L, ICP diagnosis before third trimester, or underlying hepatic disease history
Neonatology: Anticipated preterm delivery or high-risk cases

Saturday, June 20, 2026

Chicken pox in pregnancy Management protocol

Chickenpox (Varicella) in Pregnancy

Maternal Medicine · Clinical Reference

Chickenpox (Varicella)
during Pregnancy

A protocol for prevention, post-exposure prophylaxis, and active infection — for mother and baby.

BASED ON RCOG & ACOG GUIDELINES

Initial Assessment & Prevention

Determine Immunity

At the first antenatal visit, take a detailed history of prior chickenpox or shingles infection, or varicella vaccination.

If Non-Immune

Advise avoidance of contact with anyone with chickenpox or shingles.
Offer vaccination postnatally — not during pregnancy.
Delay conception 1 month after vaccination.

Management Following Exposure

Step 1

Determine "Significant Exposure"

Contact type: face-to-face, or same small room for 15+ minutes, with someone who has chickenpox, disseminated shingles, or exposed shingles lesions.
Infectious window: 24 hours before rash appears → 5 days after.

Step 2

Determine Susceptibility

Urgent VZV IgG blood test for a susceptible woman with significant exposure.

A reliable history of chickenpox, or two vaccine doses, is itself sufficient evidence of immunity in an immunocompetent woman — no further testing needed.

Step 3

Post-Exposure Prophylaxis (PEP)

Offered if VZV IgG negative (non-immune).

First-line

Oral Antiviral Therapy

Aciclovir or valaciclovir — now the recommended first choice. Given Day 7 to Day 14 after exposure.

Second-line

VZIG

Considered if antivirals are contraindicated (e.g. renal impairment) or not tolerated. A blood product giving passive immunity; effective up to 10 days after contact.

Management of Active Chickenpox

Immediate Action

Contact the healthcare provider immediately, and isolate from other pregnant women.

Risk Profile

10–20%

Pregnant women who develop pneumonia

0.4–2.0%

Risk of fetal varicella syndrome

1st / early 2nd

Trimester = highest fetal risk window

Maternal risks also include hepatitis and encephalitis. Fetal risk depends on gestational age at infection.

Treatment

Route	When indicated
Oral aciclovir	Presenting within 24 hours of rash onset, ≥20 weeks gestation. Use before 20 weeks should also be considered.
IV aciclovir	All pregnant women with severe chickenpox or signs of complications (e.g. respiratory symptoms).

High-Risk Window: Late Pregnancy

Maternal infection from 5 days before to 2 days after delivery carries a high risk of neonatal death. Requires specialist management in a unit with neonatology expertise.